foliglurax
Small moleculeexperimental
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. It reached phase II clinical trials, but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints. — Wikipedia
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02639221)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 4POSITIVE ALLOSTERIC MODULATOR
GRM4 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
O/N=c1\cc(-c2cc3sccc3cn2)oc2ccc(CCCN3CCOCC3)cc12- Mol. weight
- 421.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFoliglurax ↗
- ChEMBLCHEMBL4089083 ↗
Also known as
- foliglurax
- foliglurax
- pxt002331
- pxt002331
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04275115 | Phase 1 | Feb 10, 2020 | Lundbeck |
| NCT04322227 | Phase 1 | Jan 23, 2020 | Lundbeck |
| NCT04175132 | Phase 1 | Nov 12, 2019 | Lundbeck |
| NCT04002895 | Phase 1 | Jun 30, 2019 | Lundbeck |
| NCT03331848 | Phase 2 | Jan 15, 2018 | Prexton Therapeutics |
| NCT03162874 | Phase 2 | Jun 22, 2017 | Prexton Therapeutics |
| NCT02639221 | Phase 1 | Jan 1, 2016 | Prexton Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 4 | 4 | 1 | 2019 |
| Prexton Therapeutics | For profit | 3 | 3 | 2 | 2016 |
2 organizations
Page 1 / 1